Filing Details
- Accession Number:
- 0001209191-23-012994
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-02-24 20:28:47
- Reporting Period:
- 2023-02-22
- Accepted Time:
- 2023-02-24 20:28:47
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1706431 | Vir Biotechnology Inc. | VIR | Biological Products, (No Disgnostic Substances) (2836) | 812730369 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1820108 | J. Steven Rice | C/O Vir Biotechnology, Inc. 499 Illinois Street, Suite 500 San Francisco CA 94158 | Chief Administrative Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2023-02-22 | 73,000 | $0.00 | 110,209 | No | 4 | A | Direct | |
Common Stock | Disposition | 2023-02-23 | 1,795 | $25.97 | 108,414 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | A | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Acquisiton | 2023-02-22 | 46,000 | $0.00 | 46,000 | $27.01 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
46,000 | 2033-02-21 | No | 4 | A | Direct |
Footnotes
- Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan.
- Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units.
- 25% of the shares subject to the stock option vest and become exercisable on February 22, 2024, and the remainder vest in 36 equal monthly installments thereafter.